A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Phase 2 Completed 800 enrolled GlaxoSmithKline

RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to assess immune response and safety of various potencies of an investigational chickenpox vaccine given to healthy children 12 to 15 months of age.

Timeline

Start: 2022-02-03
Primary completion: 2024-02-09
Completion: 2024-06-13

Publications

Habib MA, Domachowske JB, Senders S, Korbal P, Gassama FD, Debrus S, Benedek P, Povey M, Poder A; VNS20-006 study group. Immunogenicity and safety of an investigational varicella zoster vaccine in toddlers aged 12-15 months: results of a phase II, controlled, randomized trial. Vaccine. 2026 Apr 19;79:128439. doi: 10.1016/j.vaccine.2026.128439. Epub 2026 Mar 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VNS vaccine	Vaccine	—	Subcutaneous
Comparator	Varivax	Vaccine	—	Subcutaneous
Background	Havrix	Vaccine	—	Intramuscular
Background	Measles, mumps, and rubella vaccine	Vaccine	—	Subcutaneous
Background	Prevnar 13	Vaccine	—	Intramuscular

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Summary

Timeline

Publications

Drugs

Indications